Trial · NCT06632444
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444, Phase 3, Recruiting, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis. Trials, record NCT06632444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06632444
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- NCT number
- NCT06632444
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,800 participants, estimated
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
- Interventions
- Survodutide, Placebo
- First posted
- 2024-10-09
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score | Baseline and at Week 52. | |
| Primary | Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH | Baseline and at Week 52. | |
| Primary | Part 2: Time to first occurrence of any of components of the composite endpoint consisting of progression to cirrhosis, all-cause mortality, liver transplant, hepatic decompensation event(s), worsening of MELD score to ≥15, progression to CSPH | Up to 7 years. | Progression to cirrhosis is defined as histological fibrosis score CRN F4. MELD = Model for End-stage Liver Disease CSPH =clinically significant portal hypertension |
| Secondary | Key secondary endpoint part 1: Percentage change from baseline in body weight [kg] | Baseline and at Week 52. | |
| Secondary | Key secondary endpoint part 1: Absolute change from baseline in glycosylated haemoglobin (HbA1c) [%] | Baseline and at Week 52. | This endpoint is specified only for the participants with type 2 diabetes mellitus. |
| Secondary | Key secondary endpoint part 1: Absolute change from baseline in enhanced liver fibrosis (ELF) score | Baseline and at Week 52. | |
| Secondary | Key secondary endpoint part 1: Absolute change from baseline in liver stiffness [kPa] assessed by vibration-controlled transient elastography (VCTE) | Baseline and at Week 52. | |
| Secondary | Key secondary endpoint part 1: Achievement of no progression of fibrosis assessed by central pathology (yes/no) | Baseline and at Week 52. | |
| Secondary | Key secondary endpoint part 2: Percentage change from baseline in body weight [kg] | At baseline and at Week 114 | |
| Secondary | Key secondary endpoint part 2: Absolute change from baseline in HbA1c [%] | At baseline and at Week 114 | This endpoint is specified only for the participants with type 2 diabetes mellitus. |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06632444
GET https://conductscience.org/api/trials/v1/NCT06632444/registered?page=2